Cargando…
An in vivo large-scale chemical screening platform using Drosophila for anti-cancer drug discovery
Anti-cancer drug development involves enormous expenditure and risk. For rapid and economical identification of novel, bioavailable anti-tumour chemicals, the use of appropriate in vivo tumour models suitable for large-scale screening is key. Using a Drosophila Ras-driven tumour model, we demonstrat...
Autores principales: | Willoughby, Lee F., Schlosser, Tanja, Manning, Samuel A., Parisot, John P., Street, Ian P., Richardson, Helena E., Humbert, Patrick O., Brumby, Anthony M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Company of Biologists Limited
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3597034/ https://www.ncbi.nlm.nih.gov/pubmed/22996645 http://dx.doi.org/10.1242/dmm.009985 |
Ejemplares similares
-
In Drosophila, RhoGEF2 cooperates with activated Ras in tumorigenesis through a pathway involving Rho1–Rok–Myosin-II and JNK signalling
por: Khoo, Peytee, et al.
Publicado: (2013) -
BTB-Zinc Finger Oncogenes Are Required for Ras and Notch-Driven Tumorigenesis in Drosophila
por: Doggett, Karen, et al.
Publicado: (2015) -
Src Cooperates with Oncogenic Ras in Tumourigenesis via the JNK and PI3K Pathways in Drosophila epithelial Tissue
por: Poon, Carole L.C., et al.
Publicado: (2018) -
Cooperation of the BTB-Zinc finger protein, Abrupt, with cytoskeletal regulators in Drosophila epithelial tumorigenesis
por: Turkel, Nezaket, et al.
Publicado: (2015) -
Drosophila melanogaster: A platform for anticancer drug discovery and personalized therapies
por: Munnik, Chamoné, et al.
Publicado: (2022)